Guardians of Grail

cheapbag214s

DNDN Completes Sale Of New Jersey Immunotherapy Manufacturing Facility To Novartis Pharmaceuticals,[link widoczny dla zalogowanych]
The sale was a cash transaction totaling $43 million,[link widoczny dla zalogowanych].
The agreement between the two companies represents a positive outcome for Dendreon and its shareholders,[link widoczny dla zalogowanych], as well for the state of New Jersey. Dendreon continues making progress in improving its financial strength,[link widoczny dla zalogowanych], and the transaction with Novartis aligns with that goal as the company works to build value for its shareholders. Food and Drug Administration to treat asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer. Dendreon announced earlier this year an intention to wind down PROVENGE manufacturing at the Morris Plains facility as part of a strategic restructuring plan to accelerate the company's path to profitability and future growth.
Headquartered in Seattle,[link widoczny dla zalogowanych], Wash.,[link widoczny dla zalogowanych], Dendreon is a biotechnology company focused on targeting cancer and transforming lives through discovering,[link widoczny dla zalogowanych], developing,[link widoczny dla zalogowanych], commercializing,[link widoczny dla zalogowanych], and manufacturing novel therapeutics. Dendreon utilizes its antigen identification,[link widoczny dla zalogowanych], engineering,[link widoczny dla zalogowanych], and cell processing expertise to produce active cellular immunotherapy (ACI) product candidates that are designed to stimulate an immune response in various tumor types. PROVENGE (sipuleucel),[link widoczny dla zalogowanych], the company's first product,[link widoczny dla zalogowanych], received FDA approval in April 2010. (XCLL) Announces Contract With ZTE To Introduce Wireless Products To Chinese Marketplace (5 Comments)
SEFE,[link widoczny dla zalogowanych], Inc. (SEFE) Set To Market Harmony III Commercial-Grade Atmospheric Power Collection And Generation System (2 Comments)
Sangamo BiOSciences,[link widoczny dla zalogowanych], Inc. (SGMO) Publishes Study In Nature Medicine Demonstrating Use Of ZFN Technology To Develop Safer And More Effective Cancer Treatments (2 Comments)
相关的主题文章：

http://www.forumkbk.fora.pl/forum-ogolne,1/isabel-marant-unveils-second-us-preserve,5699.html#5899

[link widoczny dla zalogowanych]

[link widoczny dla zalogowanych]

[link widoczny dla zalogowanych]

[link widoczny dla zalogowanych]

[link widoczny dla zalogowanych]

[link widoczny dla zalogowanych]

[link widoczny dla zalogowanych]

[link widoczny dla zalogowanych]

[link widoczny dla zalogowanych]